- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,049GBP
Methylphenidate is a central nervous system stimulant used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used off-label to treat depression, obesity, and sleep disorders. It is available in both immediate-release and extended-release formulations. Methylphenidate is one of the most commonly prescribed medications for mental disorders, and is often used in combination with other medications. It is generally well-tolerated, but can cause side effects such as insomnia, headaches, and decreased appetite.
Methylphenidate is a key player in the mental disorders drugs market, which is expected to grow in the coming years due to increasing prevalence of mental health disorders and rising awareness of mental health issues. The market is also driven by the increasing availability of generic versions of the drug, as well as the development of novel formulations.
Some companies in the methylphenidate market include Shire, Novartis, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more